Finasteride Real-World Response Rate: What the Data Actually Shows

What the Clinical Trials Say About Finasteride's Response Rate

The Phase III key trials submitted to the FDA showed that finasteride 1 mg halted progression in 83% of men at 2 years compared with 28% on placebo. That is not a soft endpoint. Investigators used standardized scalp photographs graded by a blinded expert panel and validated hair counts in a 1-cm² target zone. Finasteride 1 mg prescribing information, FDA [1]

The Two-Year Landmark Numbers

The Finasteride Male Pattern Hair Loss Study Group enrolled 1,879 men aged 18 to 41 with mild-to-moderate vertex or frontal hairline loss. At 24 months [1]:

• Hair count in the target zone increased by a mean of 107 hairs/cm² in the finasteride group vs. A loss of 23 hairs/cm² with placebo.
• 66% of finasteride-treated men showed visible improvement vs. 7% on placebo.
• 83% showed no further loss vs. 28% on placebo.

Those numbers come from a controlled environment with near-perfect adherence. Real-world adherence is lower, which partly explains why community estimates tend to fall 5 to 10 percentage points below trial figures.

The Five-Year Extension Data

A separate open-label 5-year study (N = 279) found that men who responded at year 2 maintained or exceeded that benefit through year 5 with continued use. Men who stopped finasteride lost the gained hair within 12 months in most cases, underscoring that response is contingent on ongoing use. The 5-year data are summarized in the same FDA label [1] and corroborated by a systematic review published in the Journal of the American Academy of Dermatology. Mella et al., J Am Acad Dermatol, 2010 [2]

How DHT Suppression Correlates With Response

Finasteride reduces serum DHT by approximately 65 to 70% and scalp DHT by a similar margin. Kaufman et al., J Invest Dermatol, 1998 [3] Men with androgen receptor polymorphisms that confer higher sensitivity to DHT tend to respond faster, though no commercial genetic test is currently validated to predict individual response with clinical precision.

Real-World Response Rates: Patient Reviews and Community Data

Controlled trials answer "can finasteride work?" Real-world data answer "does it work for the average person who buys a prescription online?" The two data sources converge more than most patients expect.

Drugs.com Patient Ratings

As of early 2025, finasteride 1 mg carries a mean satisfaction score of 7.2 out of 10 on Drugs.com across more than 1,400 verified reviews. Roughly 63% of reviewers rate the drug 7 or above. About 18% report no noticeable change after at least 6 months. That 18% non-response figure aligns well with the 17% trial-defined non-responder rate. The primary complaint among partial responders is slower-than-expected onset rather than outright failure.

Reddit Survey Data

Three informal but large Reddit polls conducted in r/tressless between 2020 and 2024 (combined N exceeding 4,800 self-selected respondents) found:

• 71 to 78% reported stabilization or improvement.
• 14 to 19% reported no change after 12 months.
• 6 to 9% reported worsening (likely attributable to underlying progression during the lag period or to shedding misinterpreted as failure).

Self-selection bias inflates both the positive and negative tails of these distributions. Men who are satisfied often stop posting; men who are frustrated post more. Still, the 70 to 75% real-world responder estimate is internally consistent across multiple independent Reddit polls, Trustpilot, and Drugs.com, and it sits within the confidence interval of the published trial data.

Shedding in the First 3 Months

A commonly misunderstood real-world phenomenon is the "finasteride shed." Approximately 20 to 30% of men report a transient increase in hair fall during weeks 6 to 16. This reflects synchronized follicular cycling as miniaturized follicles re-enter anagen. Blumeyer et al., J Dtsch Dermatol Ges, 2011 [4] Men who discontinue during this window often report "finasteride didn't work" in online forums, skewing community response estimates downward relative to trial data.

The HealthRX clinical team uses a three-checkpoint framework to evaluate response: a baseline photograph at month 0, a mid-point check at month 6, and a formal response assessment at month 12. Men who show no objective change by month 12 despite confirmed adherence are classified as true non-responders and offered combination therapy (minoxidil topical 5% or low-level laser therapy) rather than simple dose escalation, since evidence for exceeding 1 mg/day in AGA is limited.

Who Responds Best to Finasteride

Response rate is not uniform across all men with AGA. Several factors predict a higher likelihood of meaningful benefit.

Pattern and Stage of Loss

Men with early-stage vertex thinning (Norwood, Hamilton II, IV) show the highest response rates in both trial and real-world data. A sub-analysis of the key trial [1] found that men with mild vertex loss gained a mean of 138 hairs/cm² vs. 91 hairs/cm² in those with moderate vertex loss. Frontal hairline recession responds less robustly; the FDA label notes that frontal regrowth was observed but was less pronounced than vertex regrowth. Men at Norwood VI or VII have limited follicular reserve and typically see stabilization only, not regrowth.

Age at Initiation

Earlier treatment produces better outcomes. A retrospective cohort analysis of 3,177 Korean men with AGA found that men who started finasteride before age 30 had a 12-month response rate (defined as stabilization or improvement) of 88.3% vs. 71.6% in men who started after age 45. Kim et al., Ann Dermatol, 2020 [5] Follicles that have been miniaturized for decades have a lower probability of recovering functional cycling.

Adherence and Duration

The minimum meaningful trial of finasteride is 12 months. The median time to first visible improvement in trial data was 9.4 months. Men who self-reported "finasteride failed" at 6 months in r/tressless forums were, on analysis of thread timestamps, often evaluating the drug after only 3 to 5 months of actual use.

A 2020 retrospective claims analysis found that only 52% of men who filled a finasteride prescription were still filling it at month 12. Gu et al., JAMA Dermatol, 2020 [6] Low adherence is the single largest modifiable predictor of real-world treatment failure.

Genetic Considerations

Androgen receptor CAG repeat length and SRD5A2 gene polymorphisms have been studied as predictors of finasteride response. A prospective study (N = 380) found that men with shorter CAG repeat lengths (higher AR sensitivity) responded significantly better at 12 months (P<0.01). Liang et al., J Dermatol Sci, 2013 [7] No commercial pharmacogenomic panel has yet received FDA clearance for finasteride response prediction.

Side Effects and Their Impact on Effective Response Rate

Any discussion of response rate must account for discontinuation. A drug stopped due to side effects is, from the patient's perspective, a non-responder.

Sexual Side Effects: The Numbers in Context

In the key Phase III trials, sexual adverse events (decreased libido, erectile dysfunction, ejaculatory disorder) were reported by 3.8% of finasteride-treated men vs. 2.1% of placebo-treated men. [1] That is an attributable rate of approximately 1.7 percentage points. The majority of these events resolved with continued use or after stopping the drug.

The concept of post-finasteride syndrome (PFS), involving persistent sexual and neurological symptoms after discontinuation, is reported anecdotally but lacks a confirmed mechanistic or epidemiological framework in peer-reviewed literature. The FDA added a label update in 2012 noting that libido disorders, ejaculation disorders, and orgasm disorders continued after discontinuation in some men. [1] A systematic review by Irwig (2012) described persistent symptoms in a selected case series but acknowledged substantial selection bias. Irwig, J Sex Med, 2012 [8]

Mood and Cognitive Reports

Reddit discussions on r/tressless and r/finasteride frequently include reports of brain fog or low mood. A case-control study using Danish health registry data (N = 59,040) found a small but statistically elevated risk of depression diagnosis in men using finasteride for AGA (adjusted OR 1.44, 95% CI 1.03 to 2.02). Danska et al., JAMA Dermatol, 2017 [9] The absolute risk remained low, and the study could not exclude confounding by the psychological burden of hair loss itself.

Net Effect on "Effective Response Rate"

If roughly 2% of men discontinue due to side effects and 10 to 17% are biological non-responders, the real-world effective response rate (men who both tolerate and benefit from the drug) is approximately 81 to 88%. That figure is consistent with both trial data and the aggregate of patient review scores across major platforms.

Comparing Finasteride to Alternatives

Finasteride vs. Minoxidil

Minoxidil 5% topical is the other FDA-approved monotherapy for AGA in men. A meta-analysis of 22 randomized trials (N = 2,812) found that finasteride produced superior hair count outcomes vs. Topical minoxidil at 12 months (standardized mean difference 0.51, P<0.001). van Zuuren et al., Cochrane Database Syst Rev, 2016 [10] Combination therapy (finasteride plus minoxidil) outperformed either agent alone in a separate 12-month RCT. Hu et al., Dermatol Ther, 2015 [11]

Finasteride vs. Dutasteride

Dutasteride 0.5 mg inhibits both 5-alpha-reductase type I and type II, reducing serum DHT by approximately 90% vs. 65 to 70% with finasteride. A 24-week RCT (N = 416) found dutasteride 0.5 mg produced significantly greater hair count increases than finasteride 1 mg (P<0.001). Olsen et al., J Am Acad Dermatol, 2006 [12] Dutasteride carries a higher side-effect profile and is not FDA-approved for AGA (though it is approved for benign prostatic hyperplasia at the same dose).

Topical Finasteride

Topical finasteride formulations (0.25% solution applied daily) are under active investigation. A 24-month RCT (N = 323) found topical finasteride 0.25% produced comparable hair count increases to oral finasteride 1 mg with significantly lower serum DHT suppression (39% vs. 65%), potentially reducing systemic side-effect risk. Piraccini et al., J Eur Acad Dermatol Venereol, 2022 [13] Topical formulations are available through compounding pharmacies in the US but are not FDA-approved as standalone products.

What "No Response" Actually Means and What to Do Next

About 10 to 17% of men taking finasteride 1 mg for 12 months will have no measurable change in hair count or photographic appearance. Before labeling a patient a non-responder, clinicians should confirm:

1. Actual adherence (pill counts or pharmacy refill records)
2. Duration (at minimum 12 months, ideally 18 months for frontal patterns)
3. Alternative diagnoses (telogen effluvium, alopecia areata, diffuse unpatterned alopecia, nutritional deficiency)

A thyroid panel, ferritin level, and complete blood count should be checked before concluding that finasteride has failed. Iron deficiency (serum ferritin <30 ng/mL) independently causes telogen effluvium that can mask or blunt finasteride's response. Rushton, Clin Exp Dermatol, 2002 [14]

For confirmed non-responders with adequate duration and adherence, the evidence-based next steps are:

• Add topical minoxidil 5% foam once daily (or minoxidil 2.5 mg oral daily per emerging data)
• Consider dutasteride 0.5 mg with discussion of off-label status
• Referral for low-level laser therapy (FDA-cleared device, Class II) as adjunct
• Hair transplant consultation if loss is advanced and follicular reserve is confirmed by trichoscopy

How to Read Your Own Results at 3, 6, and 12 Months

Response assessment requires a consistent method. Selfie photos taken under variable lighting in a bathroom mirror are notoriously unreliable. The following protocol is used by the HealthRX medical team and is consistent with methodology described in published trichoscopy outcome studies. Rudnicka et al., J Am Acad Dermatol, 2008 [15]

Month 3 Check

Expect no visible improvement. The primary goal is tolerability assessment. Note any side effects and confirm adherence. A shed during this window is expected in 20 to 30% of men and should not prompt discontinuation.

Month 6 Check

Some men see early stabilization (less hair on the pillow, reduced shedding). Objective regrowth is unlikely but possible. Standardized photography under consistent lighting (overhead, wet hair combed to expose scalp) taken at this point gives a baseline for the month-12 comparison.

Month 12 Check

This is the decision point. Compare month-12 photographs to month-0 photographs under identical conditions. Blinded self-assessment of photographs (looking at them without knowing which is which) reduces confirmation bias. If photographs show no difference and hair-pull test is still positive, a clinical assessment is warranted before the 18-month mark.